Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Tarsus Pharmaceuticals Inc

Company price
73.01 USD -4.66 ( 6.00%)
Last update at 2026-11-20T21:00:00Z
VOLUME
529313
Market Cap
3660.51M

Momentum Score

…

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
72.74
Low
78.11
High
52 Week Price Range
51.57
Low
91.53
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
77.67
Dividend Yield
-
Revenue TTM
606.33M
Revenue Per Share
14.12
Gross Profit TTM
501.26M
Debt / Equity
0.27
ROE
-13.68%
Net Debt
-90.00M
ROCE
-13.00%
Diluted EPS TTM
-1.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -64.36M -115.55M -135.89M -62.09M -13.77M
Net income -66.42M -115.55M -135.89M -62.09M -13.83M
Selling general administrative 427.32M 237.31M 80.33M 44.95M 25.40M
Gross profit 420.68M 170.13M 15.85M 24.86M 54.95M
Reconciled depreciation 1.82M 1.23M 0.63M 0.33M 0.31M
Ebit -55.42M -107.70M -132.55M -62.71M -12.16M
Ebitda -53.61M -106.48M -131.67M -59.13M -10.58M
Depreciation and amortization 1.82M 1.23M 0.88M 3.58M 1.58M
Non operating income net other - - - -0.68M -1.65M
Operating income -70.97M -120.57M -143.16M -62.71M -12.16M
Other operating expenses 522.33M 303.52M 160.60M 88.53M 69.18M
Interest expense 8.94M 7.45M 3.23M 2.20M 2.88M
Tax provision 2.06M 0.00M 0.00M -0.00M 0.06M
Interest income 15.75M 15.01M 9.49M 3.50M 0.04M
Net interest income 6.81M 7.17M 6.44M 1.30M 0.04M
Income tax expense 2.06M - 0.71M -0.00M 0.06M
Total revenue 451.36M 182.95M 17.45M 25.82M 57.03M
Total operating expenses 491.64M 290.70M 159.01M 87.57M 67.11M
Cost of revenue 30.68M 12.83M 1.59M 0.95M 2.08M
Total other income expense net 6.61M 5.01M 7.26M 0.62M -1.61M
Net income from continuing ops -66.42M -115.55M -107.59M -62.09M -13.83M
Net income applicable to common shares - - - -62.09M -13.83M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 562.16M 376.99M 266.22M 227.86M 178.91M
Intangible assets 7.37M 8.33M 3.87M - -
Other current assets 14.03M 14.65M 7.87M 0.00M 4.04M
Total liab 218.73M 152.46M 69.24M 34.96M 12.18M
Total stockholder equity 343.43M 224.53M 196.99M 192.90M 166.73M
Other current liab 119.31M 52.27M 18.39M 4.80M 1.49M
Common stock 0.01M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.00M
Retained earnings -426.63M -360.21M -244.66M -108.76M -46.67M
Other liab - - - 0.05M 0.11M
Other assets - - 0.00M 0.48M 0.18M
Cash 183.64M 94.82M 224.95M 71.66M 171.33M
Total current liabilities 135.69M 80.61M 36.94M 15.43M 11.48M
Net debt -90.00M -22.37M -193.22M -51.51M -169.44M
Short term debt - 0.61M 0.40M 0.72M 1.31M
Short long term debt total 93.64M 72.45M 31.73M 20.16M 1.89M
Other stockholder equity 769.67M 584.56M 441.64M 301.73M 213.40M
Property plant equipment - - - 0.96M 0.76M
Total current assets 522.78M 356.70M 256.13M 225.38M 175.95M
Long term investments 3.87M 3.00M 0.63M 0.37M -
Net tangible assets - - - 192.90M 166.73M
Short term investments 233.63M 196.56M 2.50M 145.37M 0.48M
Net receivables 87.11M 48.06M 17.71M 3.58M 0.09M
Long term debt 72.44M 71.84M 29.82M 19.43M -
Inventory 4.37M 2.62M 3.11M 4.76M 175.68M
Accounts payable 16.39M 27.74M 18.15M 9.91M 8.68M
Accumulated other comprehensive income 0.38M 0.18M -0.00M -0.07M -
Common stock total equity - - - 0.01M 0.00M
Retained earnings total equity - - - -108.76M -46.67M
Non currrent assets other 6.39M 6.09M 1.51M 0.58M 1.13M
Non current assets total 39.38M 20.29M 10.09M 2.49M 2.96M
Capital lease obligations 0.00M 0.61M 0.40M 0.77M 1.89M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -32.26M -199.19M 35.53M -144.12M -0.59M
Change to liabilities - - - 3.48M 5.75M
Total cashflows from investing activities -42.12M -199.19M 140.60M -144.63M -0.59M
Net borrowings 0.00M 75.00M 10.00M -0.88M 20.00M
Total cash from financing activities 143.39M 154.66M 130.18M 93.99M 0.02M
Change to operating activities - - - -1.77M -2.44M
Net income -66.42M -115.55M -135.89M -62.09M -13.83M
Change in cash 88.82M -127.57M 153.29M -99.67M 3.18M
Begin period cash flow 97.38M 224.95M 71.66M 171.33M 168.15M
End period cash flow 186.20M 97.38M 224.95M 71.66M 171.33M
Total cash from operating activities -12.45M -83.03M -117.49M -49.03M 3.75M
Issuance of capital stock 134.77M 98.29M 99.38M 74.35M 0.00M
Depreciation 1.82M 1.23M 0.88M 0.33M 0.31M
Other cashflows from investing activities - -5.00M -4.00M - -
Change to inventory -1.75M -2.05M -3.11M - -
Change to account receivables -39.05M -30.14M -14.13M - -0.07M
Sale purchase of stock - - - 74.94M 0.32M
Other cashflows from financing activities 143.39M -18.63M 1.58M 19.64M -5.47M
Change to netincome - - - 13.96M 15.00M
Capital expenditures 9.86M 1.57M 5.50M 0.51M 0.59M
Change receivables - - - -3.49M -0.07M
Cash flows other operating - - - -0.20M -3.42M
Cash and cash equivalents changes - - - -99.67M 3.18M
Change in working capital 14.64M 3.84M 0.31M -0.95M 1.37M
Stock based compensation 41.72M 27.82M 19.83M 13.46M 8.46M
Other non cash items -4.21M -0.36M -2.61M 0.23M 5.79M
Free cash flow -22.31M -84.59M -123.00M -49.54M 3.16M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TARS
Tarsus Pharmaceuticals Inc
-4.66
6.00%
73.01 - 73.53 6.04 10.79 5.55 -3.23
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

17700 Laguna Canyon Road, Irvine, CA, United States, 92618

949 418 1801

370

Name Title Year Born
Dr. Bobak R. Azamian M.D. Co-Founder, Pres, CEO & Chairman NA
Dr. Bryan Wahl J.D., M.D. Gen. Counsel & Corp. Sec. 1978
Ms. Dianne C. Whitfield M.S.W. Chief HR Officer 1977
Dr. Elizabeth Yeu Lin M.D. Chief Medical Advisor & Director 1978
Dr. D. Michael Ackermann Ph.D. Consultant 1982
Mr. Leonard M. Greenstein J.D. Chief Financial Officer 1976
Dr. Seshadri Neervannan Ph.D. Chief Operating Officer 1968
Mr. David Nakasone Head of Investor Relations NA
Ms. Adrienne Kemp Sr. Director of Corp. Communications NA
Mr. Matthew Rossen M.B.A. VP of Marketing 1977

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…